
Topic
IRA Negotiation
Medicare drug price negotiation, selected-drug lists, maximum fair price, and downstream lifecycle planning.

Policy· May 27, 2026 · 12 min read

Pricing & Access· May 24, 2026 · 11 min read
SGLT2 inhibitor access landscape in 2026

Pricing & Access· May 23, 2026 · 10 min read
DOAC access landscape: Eliquis, Xarelto, Pradaxa, and Savaysa in 2026
By Ran Chen#DOAC#Coverage Access#Prior Authorization

Pricing & Access· May 22, 2026 · 15 min read
340B and IRA MFP non-duplication workflow for manufacturer teams

Pricing & Access· May 22, 2026 · 12 min read
State PDAB launch-risk watchlist for market access teams
By Ran Chen#Drug Pricing#Market Access#Payer Policy

Policy· May 21, 2026 · 8 min read
Medicare Part D redesign 2025-2026: IRA changes and access implications

Pricing & Access· May 18, 2026 · 11 min read
Jardiance vs Farxiga: label, access, and payer coverage compared

Pricing & Access· May 17, 2026 · 10 min read
Farxiga coverage guide: formulary, prior authorization, and what access teams should know

Pricing & Access· May 17, 2026 · 9 min read
Jardiance coverage guide: formularies, prior authorization, and access notes

Pricing & Access· May 16, 2026 · 11 min read
Eliquis vs Xarelto: label, access, and payer coverage compared
By Ran Chen#DOAC#Anticoagulant#Prior Authorization